Compare Target Corporation (TGT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs Twist Bioscience Corp — how do they compare? Target Corporation trades at $157.95 (market cap $73.92B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Target Corporation is far larger — about 8.8× Twist Bioscience Corp's market cap, and Target Corporation pays a 2.85% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TGT | TWST | |
|---|---|---|
Market Cap | $73.92B | $8.42B |
Sector | Consumer Cyclical | Health |
52-Week High | $169.90 | $153.10 |
52-Week Low | $83.68 | $24.16 |
Enterprise Value | $87.20B | $8.35B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target Corporation (TGT) trades at $162.71, down 1.05% on the day, with strong technical momentum and solid fundamentals. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue remains stable around $107 billion with improving profitability margins. Recent news highlights CEO Michael Fiddelke's successful turnaround strategy and the company's expanding non-merchandise revenue streams.
Target presents a balanced investment case with fair valuation metrics and strong dividend history, though competitive retail pressures and valuation expansion pose risks. Analyst consensus leans slightly bullish with a $166.67 price target, representing modest upside potential from current levels. The company's operational efficiency improvements and digital growth initiatives support continued earnings momentum.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
